Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994756877> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2994756877 endingPage "S738" @default.
- W2994756877 startingPage "S738" @default.
- W2994756877 abstract "While various therapies have been studied in relapsing-remitting multiple sclerosis populations, few therapies have been studied in secondary progressive multiple sclerosis (SPMS). The objective of this review was to assess clinical efficacy, safety and tolerability of pharmacological treatments for patients with SPMS. Embase, MEDLINE and the Cochrane Library were searched until 17 October 2018 for comparative trials assessing DMTs in adults with SPMS. Health technology assessment agency websites, key conference proceedings, and grey literature were also screened. Study quality was assessed using National Institute for Health and Care Excellence (NICE) recommended critical appraisal checklists. Out of 3478 citations screened, 23 studies were included; of these, 18 were randomized controlled trials (RCTs), and the remaining were observational. Siponimod was the only intervention to show a significant impact on both 3- and 6-month confirmed disability progression (CDP) compared to placebo. For interferon β-1a, no significant difference was seen in 3- and 6-month CDP, while for interferon β-1b, results were significantly better vs. placebo for CDP-3, while inconsistent results were reported for CDP-6 (1 study reported significant improvement and the other not). One included study for natalizumab vs. placebo did not show statistical significance for CDP-6. In terms of annualized relapse rates (ARR), a significant relapse reduction vs. placebo was seen for interferon (two studies for interferon β-1a, and one for interferon β-1b), natalizumab and siponimod. One study included on adipose-derived mesenchymal stem cells was not powered to demonstrate efficacy differences. Idebenone demonstrated no significant change in disability and neurophysiological parameters. All treatments were generally well tolerated. Findings from this SLR suggest an improvement in outcomes on treatment with some DMTs compared to placebo. In the absence of active controlled RCTs, indirect comparisons are needed to assess the comparative efficacy of treatments." @default.
- W2994756877 created "2019-12-26" @default.
- W2994756877 creator A5048625654 @default.
- W2994756877 creator A5060223156 @default.
- W2994756877 creator A5061234356 @default.
- W2994756877 creator A5077800538 @default.
- W2994756877 date "2019-11-01" @default.
- W2994756877 modified "2023-09-25" @default.
- W2994756877 title "PND8 A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS" @default.
- W2994756877 doi "https://doi.org/10.1016/j.jval.2019.09.1779" @default.
- W2994756877 hasPublicationYear "2019" @default.
- W2994756877 type Work @default.
- W2994756877 sameAs 2994756877 @default.
- W2994756877 citedByCount "0" @default.
- W2994756877 crossrefType "journal-article" @default.
- W2994756877 hasAuthorship W2994756877A5048625654 @default.
- W2994756877 hasAuthorship W2994756877A5060223156 @default.
- W2994756877 hasAuthorship W2994756877A5061234356 @default.
- W2994756877 hasAuthorship W2994756877A5077800538 @default.
- W2994756877 hasBestOaLocation W29947568771 @default.
- W2994756877 hasConcept C126322002 @default.
- W2994756877 hasConcept C142724271 @default.
- W2994756877 hasConcept C168563851 @default.
- W2994756877 hasConcept C1862650 @default.
- W2994756877 hasConcept C197934379 @default.
- W2994756877 hasConcept C203014093 @default.
- W2994756877 hasConcept C204787440 @default.
- W2994756877 hasConcept C27081682 @default.
- W2994756877 hasConcept C2776478404 @default.
- W2994756877 hasConcept C2778375690 @default.
- W2994756877 hasConcept C2779134260 @default.
- W2994756877 hasConcept C2780640218 @default.
- W2994756877 hasConcept C2781004633 @default.
- W2994756877 hasConcept C2908698914 @default.
- W2994756877 hasConcept C2994247566 @default.
- W2994756877 hasConcept C71924100 @default.
- W2994756877 hasConceptScore W2994756877C126322002 @default.
- W2994756877 hasConceptScore W2994756877C142724271 @default.
- W2994756877 hasConceptScore W2994756877C168563851 @default.
- W2994756877 hasConceptScore W2994756877C1862650 @default.
- W2994756877 hasConceptScore W2994756877C197934379 @default.
- W2994756877 hasConceptScore W2994756877C203014093 @default.
- W2994756877 hasConceptScore W2994756877C204787440 @default.
- W2994756877 hasConceptScore W2994756877C27081682 @default.
- W2994756877 hasConceptScore W2994756877C2776478404 @default.
- W2994756877 hasConceptScore W2994756877C2778375690 @default.
- W2994756877 hasConceptScore W2994756877C2779134260 @default.
- W2994756877 hasConceptScore W2994756877C2780640218 @default.
- W2994756877 hasConceptScore W2994756877C2781004633 @default.
- W2994756877 hasConceptScore W2994756877C2908698914 @default.
- W2994756877 hasConceptScore W2994756877C2994247566 @default.
- W2994756877 hasConceptScore W2994756877C71924100 @default.
- W2994756877 hasLocation W29947568771 @default.
- W2994756877 hasOpenAccess W2994756877 @default.
- W2994756877 hasPrimaryLocation W29947568771 @default.
- W2994756877 hasRelatedWork W1966047811 @default.
- W2994756877 hasRelatedWork W1986598933 @default.
- W2994756877 hasRelatedWork W2001155665 @default.
- W2994756877 hasRelatedWork W2003042623 @default.
- W2994756877 hasRelatedWork W202460821 @default.
- W2994756877 hasRelatedWork W2030348591 @default.
- W2994756877 hasRelatedWork W2164556363 @default.
- W2994756877 hasRelatedWork W2329926589 @default.
- W2994756877 hasRelatedWork W2565772585 @default.
- W2994756877 hasRelatedWork W2982358067 @default.
- W2994756877 hasVolume "22" @default.
- W2994756877 isParatext "false" @default.
- W2994756877 isRetracted "false" @default.
- W2994756877 magId "2994756877" @default.
- W2994756877 workType "article" @default.